DOJ sues former laboratory executives over $13.7 million in allegedly unnecessary Medicare testing
Oct 4, 2026 edition · GC-2026-0104 · Published 2026-10-04 · Version 2 · Pending litigation
DOJ's pending laboratory complaint alleges $13.7 million in Medicare payments tied to mass-event genetic tests and added respiratory panels without valid individualized ordering.
What happened
DOJ's September 2026 announcement describes a False Claims Act complaint against former Capstone Diagnostics executives and associated entities involving approximately $13.7 million in Medicare payments from 2019 through 2021. The government alleges two schemes: genetic testing at church-sponsored health fairs and religious conferences without physician requests, and medically unnecessary respiratory panels added to COVID-19 testing for senior-living communities. DOJ intervened September 4 in the whistleblower case brought by a former laboratory manager. The civil allegations remain unproven; the announcement does not report a judgment against these defendants.
The alleged order-generation methods included using physicians' identities and copied signatures without permission, community-wide or chain-wide standing orders, standardized diagnosis codes, sales personnel entering orders and remuneration tied to test volume. DOJ separately identified settlements with Capstone and its owner and with its billing company; those resolutions do not adjudicate the pending defendants' liability. The release also states that criminal charges against one former executive were pending. An operational review should therefore focus on the identified control patterns without treating either the civil complaint or indictment as a conviction: individualized clinical authorization, valid signatures, medical necessity and separation of sales activity from ordering.
Scope and timing
- Authority status
- Pending litigation
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, Georgia
Why it matters
The complaint links multiple laboratory safeguards that can fail together, especially when standardized ordering and marketer incentives replace patient-specific clinical support.
Recommended action
Sample genetic and respiratory claims for treating-provider authorization, signature validity, patient-specific diagnoses and necessity. Review standing orders, sales access and marketer compensation, escalating copied-signature or volume-linked patterns.
Case details
- agencies
- U.S. Department of Justice, HHS Office of Inspector General, Federal Bureau of Investigation
- entities
- Former Capstone Diagnostics executives and associated entities
- action Type
- Civil complaint
- event Date
- 2026-09-17
- alleged Conduct
- Alleged medically unnecessary genetic and respiratory panel testing generated through mass events, copied signatures, standing orders, standardized diagnoses, sales ordering, and kickbacks.
- resolution
- Complaint filed. Liability has not been determined.
Operational lessons
- Laboratory tests need individualized treating-provider orders.
- Sales personnel should not create clinical orders.
- Standing orders and copied signatures require focused monitoring.
- Marketer compensation must not reward federally reimbursed test volume.
Related coverage
The alleged ordering and payment patterns are direct Medicare program-integrity indicators. Medicare & Medicaid →
Sources
- DOJ Sues Former Georgia Lab Execs for Defrauding Medicare by Targeting Faith-Based Communities and SeniorsOfficial · U.S. Attorney Office, Northern District of Georgia · 2026-09-17 · Source review 2026-09-20
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →